UNI 494
Alternative Names: Nicorandil prodrug - Unicycive Therapeutics; UNI-494Latest Information Update: 08 May 2025
At a glance
- Originator Sphaera Pharma
- Developer Unicycive Therapeutics
- Class Small molecules; Urologics
- Mechanism of Action KATP channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute kidney injury
- Preclinical Delayed graft function; Kidney disorders
Most Recent Events
- 07 Jan 2025 Unicycive Therapeutics completes a phase-I clinical trials in Acute kidney injury (In volunteers) in United Kingdom (PO, Capsule) (EudraCT2022-003223-17)
- 31 May 2024 Unicycive Therapeutics has patent protection for UNI 494 in USA and Europe
- 31 May 2024 Unicycive Therapeutics has patents pending for UNI 494 in USA, Japan, China and the World